Media
Hua Medicine to present additional dorzagliatin trials data at ADA 2021
June 21, 2021 – China, Shanghai
Hua Medicine (the "Company", Stock Code: 2552.HK), today announced that the Company will be giving 3 important presentations, presenting additional clinical data from several trials of its global first-in-class drug, glucokinase activator (GKA) dorzagliatin, at the 81st American Diabetes Association (ADA) Annual Scientific Sessions. The ADA Annual Scientific Sessions will be held online from June 25 to 29, 2021.
The ADA annual scientific conference is the largest and most important Diabetes Conference in the world. Every year, researchers and participants from over ten thousand diabetes fields from around the world are attracted to report and exchange the significant progress in current diabetes research and treatment. Since 2014, as a leader in global diabetes innovation, Hua Medicine has presented important clinical achievements annually at the ADA annual scientific conference.
Contents of Hua Medicine Presentation
Oral Presentation | |
Report code: | 235-OR |
Report Topic: | Dorzagliatin as a Glucose Sensitizer Achieved Sustained Glycemic Control with Good Safety Profiles in Drug-Naïve T2D Patients in a 52-Week Phase 3 Monotherapy Trial (SEED) |
Report Date & Time: | 28th June 8:15am - 8:30am (U.S. Eastern Time) |
Reporter: | Professor Dalong Zhu, Director of the Chinese Medical Association's diabetes branch and the department of endocrinology of the Nanjing Drum Tower Hospital |
Theme Area: | Novel Therapeutic Agents and A pproaches |
ePoster Presentations | |
ePoster code: | 763-P |
ePoster Title: | Dorzagliatin Add-On to Metformin Achieved Sustained Efficacy and Good Safety in T2D Patients in a Phase 3 Trial (DAWN) |
ePoster Presentations | |
ePoster code: | 117-LB |
ePoster Title: | Glucokinase Activator (HMS5552) Release in T2D Synergistic with Empagliflozin in Optimizing Beta-Cell Function（HMM0111&HMM0112） |
About Dorzagliatin
Dorzagliatin is an investigational first-in-class, dual-acting glucokinase activator, designed to control the progressive, degenerative nature of diabetes by restoring glucose homeostasis in patients with Type 2 diabetes. By addressing the defect of the glucose sensor function of glucokinase, dorzagliatin has the potential to restore the impaired insulin and GLP-1 secretion of patients with Type 2 diabetes and serve as a cornerstone therapy targeting the root cause of the disease. Two Phase III registration trials for dorzagliatin monotherapy and the combination of dorzagliatin and metformin have been completed in China, as well as studies on drug mechanism synergy with sitagliptin (DPP-4 inhibitor) and empagliflozin (SGLT-2 inhibitor). The Company has obtained the “Drug Manufacturing Permit” of dorzagliatin issued by the Shanghai Municipal Drug Administrative Bureau, and has submitted its NDA to the National Medical Products Administration, so as to realize the “First in Global, Start from China” mission objective for the benefit of diabetic patients worldwide.
About Hua Medicine
Hua Medicine is a leading, innovative biotechnology company in China focused on developing novel therapies for diseases with unmet medical needs. Founded by an experienced group of entrepreneurs and international investment firms, Hua Medicine advanced a first-in-class oral drug for the treatment of T2DM into NDA-enabling stage and it has successfully completed two Phase III registration trials in China for dorzagliatin. The Company has initiated product life-cycle management studies of this novel diabetes therapy and advanced its use in personalized diabetes care. Hua Medicine is working closely with disease experts and regulatory agencies in China and across the world to advance diabetes care solutions for patients worldwide.
For more information
Hua Medicine
Website: www.thanosbox.com
Investors
Email: ir@thanosbox.com
Media
Email: pr@thanosbox.com
沪ICP备14036654号-1
沪公网安备 31011502013809号 Privacy Statement Terms of Use
